KEI testimony at March 8, 2018 USTR Special 301 hearing, focusing on US compulsory licensing of patents

On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading

Innogenetics v. Abbott – 2008 compulsory license granted for HCV genotyping kits under eBay v. MercExchange

This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading

United States non-voluntary use of patents

Read first: Statutory authority for compulsory licenses on patents in the United States KEI Workshop: Feb 24, 2017 – U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents. There is a Video of the event here here. Non-voluntary… Continue Reading

CAR-T

Gilead 10-Q, 3rd quarter 2017 If any party is successful in establishing exclusive rights to axi-cel, our anticipated revenues and earnings from the sale of that product could be adversely affected. In October 2017, we acquired Kite, which is now… Continue Reading

Orphan works (copyright and related rights)

KEI has advocated for copyright exceptions to expand access to works protected by copyright and related rights, when the owners of the rights cannot be located after reasonably diligent searches. Among the areas where KEI has be particularly active is… Continue Reading

Compulsory licensing

Global norms on compulsory licensing Country experiences Compulsory licensing in the United States Statutory authority for compulsory licenses on patents in the United States Compulsory licensing as a remedy to anticompetitive practices Compulsory licensing under the Bayh-Dole Act Compulsory licensing… Continue Reading